Interventional Oncology in Oligometastatic Disease: Closing the Treatment Gap
Metastasis-directed therapy (MDT) is currently an increasingly established component of oligometastatic disease (OMD) management. Interventional radiology (IR) offers a broad range of image-guided MDT options, including thermal ablation, nonthermal ablation, and transarterial therapies, yet remains structurally underutilized within multidisciplinary treatment pathways. As a result, IR-delivered therapies are often evaluated in late-referral or salvage contexts, producing comparative outcome data that are heavily influenced by selection bias and confounding by indication. Interpretation of the IR evidence base is further complicated by evidentiary lag, as many mature outcome data derive from earlier-generation technologies that may not fully reflect contemporary practice. This is particularly important because, in carefully selected patients and in the limited settings where randomized or well-controlled comparative data exist, IR-delivered therapies can achieve oncologic outcomes comparable with more invasive modalities while substantially reducing treatment morbidity, recovery time, hospital stay, and cost. MDT selection in OMD is inherently multidimensional: Durable local control must be weighed against treatment burden, repeatability, preservation of systemic therapy options, logistical feasibility, and patient preference. We summarize the evidence supporting IR-based MDT across hepatic, pulmonary, adrenal, nodal, osseous, and emerging neuro-oncologic OMD sites, with comparison with established surgical and radiotherapeutic approaches. We further propose a Pareto-based conceptual framework for patient-centered modality selection, in which multiple treatment strategies may represent efficient trade-offs rather than a single universally optimal approach. Interventional oncology should be viewed not as a salvage service but as an essential fourth pillar of cancer care alongside medical, surgical, and radiation oncology.
Authors
- Vamshi Krishna Kotha (ORCID: https://orcid.org/0000-0003-1690-3135)
- Jan Grendar (ORCID: https://orcid.org/0000-0003-3158-0565)
- Petra Grendarova (ORCID: https://orcid.org/0000-0003-0438-8383)
- Olga Vornicova (ORCID: https://orcid.org/0000-0001-6979-2120)
- Justin T. Blackman (ORCID: https://orcid.org/0000-0001-6996-878X)
Institutions
- Island Health (CA)
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- BC Cancer – Victoria (CA)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1200/op-26-01000
- Primary Topic
- Management of metastatic bone disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00